TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Siva, Shankar; Chesson, Brent; Bressel, Mathias; Pryor, David; Higgs, Braden; Reynolds, Hayley M.; Hardcastle, Nicholas; Montgomery, Rebecca; Vanneste, Ben; Khoo, Vincent; Ruben, Jeremy; Lau, Eddie; Hofman, Michael S.; De Abreu Lourenco, Richard; Sridharan, Swetha; Brook, Nicholas R.; Martin, Jarad; Lawrentschuk, Nathan; Kron, Tomas; Foroudi, Farshad

doi:10.1186/s12885-018-4916-2

Table 1 Review of SABR literature for primary RCC

From: TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Author / Year	Patients	Follow-up (months - Median or Mean)	Average marginal dose (Gy)	Outcome - Crude Local control	Estimated 2 year LC	Overall Survival Median	Toxicities
Chang et al. [7] 2016	16	19	30-40Gy in 5 fractions	100%	NR	NR	1 grade 2 acute toxicity and 2 grade 4 late toxicities
Gilson et al. [8] 2006	33	17	Median 40Gy in 5 fractions	94%	92	NR	NR
Lo et al. [9] 2014	3	21.7	40Gy in 5 fractions	100%	NR	NR	Early: 1 x Grade 1 nausea Late: nil
McBride et al. [10] 2013 (abstract) [prospective]	15	36.7	Median 33Gy in 3 fractions	87% 1 failure at 30.7 mo 1 failure at 31.2 mo	NR	NR	1 x Grade 3 renal toxicity 5 x Grade 1 fatigue 2 x Grade 1 nausea
Nair et al. [27] 2013	3	13.3	39Gy in 3 fractions	100%	NR	NR	Early: 1 x Grade 1 nausea Late: Nil
Nomiya et al. [28] 2008	10	57.5	Median 4.5Gy x 16fx	100%	100	5 year OS 74%	10% Grade 4 toxicity, no other toxicities > Grade 1
Qian et al. [29] 2003 (abstract)	20	12	40Gy in 5 fractions	93%	86	NR	NR
Pham et al. [15] 2014 [prospective]	20	6	26Gy in 1 fraction 42Gy in 3 fractions	NR	NR	NR	60% Grade 1–2 No Grade 3, Grade 4
Ponksy et al. [30] 2015 [prospective]	19	13.7	Max 48Gy in 4 fractions	NR	NR	NR	5.2% Grade 2, 15.8% Grade 3–4
Siva et al. [16] [prospective]	33	24	26Gy in 1 fraction 42Gy in 3 fractions	97%	100%	2 year OS 92%	78% Grade 1–2 3% Grade 3
Svedman et al. [31] 2006 [prospective]	5	52	40Gy in 4 or 5 fractions, 45Gy in 3 fractions	80%	91	Median survival 32 months	89% Grade 1–2, 4% Grade 3
Svedman et al. [32] 2008	7	39	40Gy in 4 fractions	86%	91	NR	58% Grade 1–2, nil else
Teh et al. [33] 2007 (abstract)	2	9	24Gy–48Gy in 3–6 fx	100%	100	NR	NR
Staehler et al. [18] 2015 ^b [prospective]	30^a	28.1	25Gy in 1 fraction	98% (at 9mo) ^b	NR	Not attained after median 28.1 months⁺	13% Grade 1–2 nil else
Wang et al. [13] 2014	9	38.3	36-51Gy to 50% isodose line at 3-5Gy per fraction	5 year LC 43%	NR	5 year OS 35%	Early: 44% Grade 1 (GI, haem.) Late: 22% Grade 2 (GI)
Wersall et al. [34] 2005	8	37	40Gy in 4 or 5 fractions, 45Gy in 3 fractions	100%	100	Median survival 58+ months	20% Grade 1–2, 19% Grade 3, nil Grade 4+

^a report included an additional 15 patients with Transitional cell carcinoma;
^b pooled results with patients treated for TCC
NR not reported, Gy Gray

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us